Aura Biosciences, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on June 20, 2024, specifically the Company's 2024 Annual Meeting of Stockholders. The filing details the outcomes of shareholder votes and corporate governance amendments.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and does not contain financial performance data.
Material Changes and Corporate Actions
- Charter Amendment Approved: Stockholders approved an amendment to the Tenth Amended and Restated Certificate of Incorporation to limit the liability of certain officers as permitted by the Delaware General Corporation Law (DGCL). The amendment became effective upon filing with the Delaware Secretary of State on June 20, 2024.
- Director Elections: Stockholders elected Antony Mattessich and Sapna Srivastava, Ph.D., as Class III directors to serve until the 2027 Annual Meeting.
- Accounting Firm Ratification: Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
Voting Results
| Proposal | Votes For | Votes Against | Abstentions | Broker Non-Votes |
|---|---|---|---|---|
| Election of Directors (Antony Mattessich) | 28,299,345 | 4,803,231 (Withheld) | N/A | 5,639,555 |
| Election of Directors (Sapna Srivastava) | 31,894,914 | 1,207,662 (Withheld) | N/A | 5,639,555 |
| Charter Amendment (Officer Exculpation) | 31,222,608 | 1,699,497 | 180,471 | 5,639,555 |
| Ratification of Auditors | 38,734,848 | 5,843 | 1,440 | N/A |
Note: Total shares entitled to vote were 49,533,018. Shares present or represented by proxy were 38,742,131.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, or contingencies beyond the standard incorporation by reference to the Proxy Statement for details on the Charter Amendment.
Key Facts for Investor Verification
- Verify the specific language of the Charter Amendment filed as Exhibit 3.1 to understand the scope of officer liability limitations.
- Confirm the tenure of the newly elected directors (Class III) extends through the 2027 Annual Meeting.
- Review the definitive Proxy Statement filed on April 25, 2024, for detailed rationale behind the officer exculpation proposal.
- Note that the filing contains no financial updates; refer to the most recent 10-Q or 10-K for financial health metrics.